bluebird bio, Inc.·Healthcare

Transaction Expands Fulton's Presence in Attractive New Jersey Markets LANCASTER, Pa., April 1, 2026 /PRNewswire/ -- Fulton Financial Corporation (Nasdaq: FULT) ("Fulton") today announced the successful completion of its acquisition of Blue Foundry Bancorp (formerly Nasdaq: BLFY) ("Blue Foundry"), Rutherford, N.J.

NEW YORK--(BUSINESS WIRE)---- $OWL #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Blue Owl Capital Inc. (NYSE: OWL) failed to manage Blue Owl in an acceptable manner, breaching their fiduciary duties to Blue Owl, and whether Blue Owl and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 19, 2026, Blue Owl announced it was liquidati.

Discounted Offer is Well Below OBDC II NAV and Ignores Significant Capital Return Already Underway NEW YORK, March 13, 2026 /PRNewswire/ -- Blue Owl Capital Corporation II ("OBDC II") today announced that its Board of Directors (the "Board") has unanimously recommended that shareholders reject the unsolicited minority tender offer from Cox Capital Partners ("Cox") and Saba Capital Management, L.P. ("Saba") for up to 8,000,000 shares of OBDC II for approximately $30 million (less than 7% of the outstanding shares).

NEW YORK--(BUSINESS WIRE)---- $OWL #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Blue Owl Capital Inc. (NYSE: OWL) failed to manage Blue Owl in an acceptable manner, breaching their fiduciary duties to Blue Owl, and whether Blue Owl and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 19, 2026, Blue Owl announced it was liquidati.

LANCASTER, Pa. and RUTHERFORD, N.J.

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce that Institutional Shareholder Services Inc. (“ISS”), a leading global independent proxy advisory firm, has recommended that LabGold shareholders vote ONLY on the BLUE Form of Proxy and BLUE Voting Instruction Form (“ BLUE Proxy”) in line with LabGold's recommendations, in connection with the Corporation's Annual General and Special Meeting of Shareholders (the “Meeting”) on February 24, 2026. LabGold has recommended shareholders vote “FOR” all of the Corporation's resolutions, and “AGAINST”/”WITHHOLD” on Coloured Ties Capital Inc.'s (the “Dissident”) resolutions. The Corporation's Board of Directors (the “Board”) thanks its shareholders for the strong voting support that it has received so far.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Healthcare
Biotechnology
248
2013-06-19
0.36